Azitra (AZTR) Share-based Compensation (2022 - 2026)
Azitra's (AZTR) quarterly Share-based Compensation came in at $6149.0 in Q1 2026, down 79.77% YoY from $30402.0 in Q1 2025, and down 49.37% on a QoQ basis from $12146.0 in Q4 2025.
Azitra (AZTR) Share-based Compensation (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Share-based Compensation data on file, last reported at $6149.0 in Q1 2026.
- Quarterly Share-based Compensation fell 79.77% year-over-year to $6149.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38491.0 (down 84.05% YoY) and the FY2025 annual result came in at $62744.0, down 74.4% from the prior year.
- Share-based Compensation slipped to $6149.0 in Q1 2026, from $12146.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $143534.0 in Q3 2024 to a low of $4165.0 in Q3 2025.
- A 5-year average of $37058.3 and a median of $34170.5 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 267.35% — and 2025, when it slumped 97.1%.
- Tracing AZTR's Share-based Compensation over 5 years: stood at $29327.0 in 2022, then rose by 18.81% to $34844.0 in 2023, then declined by 4.78% to $33178.0 in 2024, then sank by 63.39% to $12146.0 in 2025, then slumped by 49.37% to $6149.0 in 2026.
- The last three Share-based Compensation figures came in at $6149.0 (Q1 2026), $12146.0 (Q4 2025), and $4165.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | 11,405.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,405.00 |
| Jun 30, 2026 | 11,405.00 |
| Mar 31, 2026 | 6,149.00 |
| Mar 31, 2026 | 6,149.00 |
| Dec 31, 2025 | 12,146.00 |
| Dec 31, 2025 | 12,146.00 |
| Sep 30, 2025 | 4,165.00 |
| Sep 30, 2025 | 4,165.00 |
| Jun 30, 2025 | 16,031.00 |
| Jun 30, 2025 | 16,031.00 |
| Mar 31, 2025 | 30,402.00 |
| Mar 31, 2025 | 30,402.00 |
| Dec 31, 2024 | 33,178.00 |
| Dec 31, 2024 | 33,178.00 |
| Sep 30, 2024 | 143,534.00 |
| Sep 30, 2024 | 143,534.00 |
| Jun 30, 2024 | 34,170.00 |
| Jun 30, 2024 | 34,170.00 |
| Mar 31, 2024 | 34,171.00 |
| Mar 31, 2024 | 34,171.00 |